UDP-200

UDP-200 is a discovery-stage therapeutic candidate being developed by Cyclarity Therapeutics for the treatment of macular degeneration. The drug utilizes a proprietary, engineered cyclodextrin platform designed to specifically bind and sequester N-retinylidene-N-retinylethanolamine (A2E), a toxic bisretinoid that accumulates as a major component of lipofuscin in the retinal pigment epithelium (RPE). By facilitating the removal or neutralization of A2E, UDP-200 aims to prevent the oxidative stress, lysosomal dysfunction, and eventual cell death associated with lipofuscin buildup, potentially offering a disease-modifying approach for conditions like age-related macular degeneration (AMD) and Stargardt disease.